+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pioglitazone up-regulates MALAT1 and promotes the proliferation of endothelial progenitor cells through increasing c-Myc expression in type 2 diabetes mellitus

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Objective: Evidence suggests that pioglitazone improves the function of endothelial progenitor cells (EPCs). However, the knowledge of its molecular mechanism remains limited. In the present study, the role of long non-coding RNA MATAL1 in modulating the number and function of EPCS in type 2 diabetes mellitus (T2DM) was characterized. Methods: Circulating EPCs were obtained from peripheral blood of healthy subjects and T2DM patients with or without pioglitazone treatment. The in vitro experiments were conducted in bone marrow-EPCs to evaluate the effect of pioglitazone and its possible mechanism.  Results: Pioglitazone increased circulating EPCs number and improved their function in T2DM patients. Transfected EPCs with siRNA-MALAT1, the increase of c-Myc protein expression induced by pioglitazone treatment was canceled. In db/db diabetic mice, a glucose tolerance test showed that pioglitazone increased glucose tolerance, which was reversed by siRNA-MALAT1. Conclusion: Pioglitazone improves the EPCs function possibly through regulating MALAT1 and c-Myc expression in T2DM. Keywords: pioglitazone; diabetes mellitus; MALAT1; endothelial function; glucose tolerant

          Related collections

          Author and article information

          Aging Pathobiology and Therapeutics
          ANT Publishing Corporation
          27 March 2020
          : 2
          : 1
          : 38-44

          All content is published under a https://creativecommons.org/licenses/by-sa/4.0/ license. Users are allowed to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material for any purpose, even commercially), as long as the authors and the publisher are explicitly identified and properly acknowledged as the original source, and the derivative is distributed under the same license as the original.


          Pathology,Medicine,Geriatric medicine,Human biology,Genetics
          endothelial function,MALAT1,Pioglitazone,glucose tolerant,diabetes mellitus


          Comment on this article